According to filings with the U.S. Securities and Exchange Commission, Calviri is raising up to $2,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Stephen Johnston played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Calviri
Calviris mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.

To learn more about Calviri, visit http://calviri.com/
Calviri Linkedin Page: https://www.linkedin.com/company/calviri/

Contact:
Stephen Johnston, Chief Executive Officer
480-205-6436
https://www.linkedin.com/in/stephen-albert-johnston-560b3126/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.